Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial

Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial NEWS PROVIDED BY Alphyn Biologics May 04, 2023, 07:30 ET Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target…

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS   Corporate: Neal Koller [email protected] (410) 690-8687   Media: Susan Thomas [email protected] (619) 540-9195